Back to results
US 11,530,270 B2Granted
Antibody targeting IL-13RA2 and use thereof
AssigneeCrage Medical Co., Limited
InventorsPeng Wang, Huamao Wang
Life of this patent
Estimating the term…
Abstract
Provided is an antibody that specifically recognizes IL-13RA2, which can be used in the manufacture of a targeting anti-tumor medicament as well as a medicament for diagnosing a tumor.
Claims13
An antibody that specifically binds interleukin-13 receptor subunit alpha 2 (IL-13RA2), wherein the antibody comprises a light chain variable region and a heavy chain variable region, and wherein the antibody comprises:
- (i) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:15;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 9, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 10, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 11;
- (ii) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:16;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 9, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 10, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 12;
- (iii) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:16;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 64, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 66, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 12;
- (iv) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:15;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 45, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 52, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 11;
- (v) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:16;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 63, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 65, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 12;
- (vi) the LCDR1 amino acid sequence shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:15;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 50, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 56, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 11;
- (vii) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:15;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 46, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 52, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 11;
- (viii) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:15;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 48, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 54, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 11;
- (ix) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:15;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 47, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 53, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 11;
- (x) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:15;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 49, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 55, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 11;
- (xi) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:15;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 51, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 57, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 11;
- or
- (xii) the LCDR1 amino acid sequence as shown in SEQ ID NO:
- 13, the LCDR2 amino acid sequence as shown in SEQ ID NO:
- 14, the LCDR3 amino acid sequence as shown in SEQ ID NO:15;
- the HCDR1 amino acid sequence as shown in SEQ ID NO:
- 49, the HCDR2 amino acid sequence as shown in SEQ ID NO:
- 58, and the HCDR3 amino acid sequence as shown in SEQ ID NO:
- 11.
82 more elements
An antibody that specifically binds interleukin-13 receptor subunit alpha 2 (IL-13RA2), wherein
- (i) the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 4 and the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 2;
- (ii) the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 4 and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 29;
- (iii) the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 4 and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 39;
- (iv) the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 4 and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 31;
- (v) the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 4 and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 35;
- (vi) the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 4 and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 33;
- (vii) the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 4 and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 37;
- (viii) the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 4 and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 41;
- or
- (viv) the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 4 and the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 43.
25 more elements
An antibody that specifically binds interleukin-13 receptor subunit alpha 2 (IL-13RA2), wherein the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 2 or an amino acid sequence at least 90% identical thereto, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:
- 4.
Dependencies are inferred from the claim text.